Skip to main content

Structural Bioinformatics Gets New Medicinal Chemist; Illumina Hires Sales Chief; and others

NEW YORK, Dec. 4-Structural Bioinformatics has appointed J. Edward Semple executive director of medicinal chemistry, the company said yesterday.


He will lead teams working on new receptor antagonists for asthma treatment, new phosphatase inhibitors for obesity and diabetes, metalloprotease inhibitors for anthrax treatment, and kinase inhibitors for breast cancer therapy.


Semple was previously executive director of chemical research at Corvas International, a biotech company developing drugs for cancer and cardiovascular disease.


Structural Bioinformatics is a privately held proteomics-based company in San Diego, Calif.



Tristan Orpin has been hired by Illumina as vice president of worldwide sales, the company said yesterday.


Orpin will be in charge of sales of the company's BeadArray and Oligator products worldwide.


He was previously vice president of sales and marketing at Sequenom.


Illumina is based in San Diego, Calif.



Genome Prairie, the Canadian genomics research non-profit, said yesterday that it had appointed Gijs van Rooijen as its chief scientific officer.


Van Rooijen is adjunct assistant professor at the University of Calgary, and was most recently head of cellular and molecular biology at SemBioSys Genetics, a Calgary-based biopharmaceutical company.


The position at Genome Prairie is newly created.



Finnish molecular biologist Eero Vuorio will chair the Council of the European Molecular Biology Laboratory in 2003, the Academy of Finland said on Nov. 29.


Vuorio is currently Professor in Molecular Biology at the University of Turku, Finland, and vice chair of the EMBL Council.


Last June, current EMBL chair Peter Gruss was named president of the German Max Planck Society, the parent organization of the Max Planck Institutes.


EMBL is an international research organization supported by 16 European countries.



Promoted? Changing jobs? GenomeWeb wants to know. E-mail Kathleen McGowan at [email protected] to appear in PEOPLE, a roundup of personnel comings and goings in genomics, that appears every Wednesday.


The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.